About Spero Therapeutics
Spero Therapeutics is a company based in Cambridge (United States) founded in 2013 by Milind Deshpande.. Spero Therapeutics has raised $114.7 million across 13 funding rounds from investors including Pfizer, HHS and RA Capital. The company has 32 employees as of December 31, 2024. Spero Therapeutics offers products and services including Tebipenem HBr and SPR720. Spero Therapeutics operates in a competitive market with competitors including Nabriva, Melinta Therapeutics, Iterum Therapeutics, Adaptive Phage Therapeutics and Paratek Pharma, among others.
- Headquarter Cambridge, United States
- Employees 32 as on 31 Dec, 2024
- Founders Milind Deshpande
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Spero Therapeutics, Inc.
-
Annual Revenue
$27.4 M-71.68as on Dec 31, 2024
-
Net Profit
$-68.57 M-400.65as on Dec 31, 2024
-
EBITDA
$-93.06 M-562.82as on Dec 31, 2024
-
Total Equity Funding
$114.7 M (USD)
in 13 rounds
-
Latest Funding Round
$9 M (USD), Post-IPO
Nov 14, 2022
-
Investors
Pfizer
& 14 more
-
Employee Count
32
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Spero Therapeutics
Spero Therapeutics is a publicly listed company on the NASDAQ with ticker symbol SPRO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Spero Therapeutics
Spero Therapeutics offers a comprehensive portfolio of products and services, including Tebipenem HBr and SPR720. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational oral carbapenem for urinary tract infections treatment.
Potential treatment for multidrug-resistant bacterial infections.
Unlock access to complete
Unlock access to complete
Leadership Team
18 people
Software Development Team
4 people
Operations Team
3 people
Data Analysis and Operations Team
2 people
Finance and Accounting
2 people
Human Resources and Administration
2 people
Product Management Team
1 people
Clinical Team
1 people
Unlock access to complete
Funding Insights of Spero Therapeutics
Spero Therapeutics has successfully raised a total of $114.7M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $9 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Post-IPO — $9.0M
- First Round First Round
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2022 | Amount | Post-IPO - Spero Therapeutics | Valuation |
investors |
|
| Jan, 2022 | Amount | Grant - Spero Therapeutics | Valuation |
investors |
|
| Jun, 2021 | Amount | Post-IPO - Spero Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Spero Therapeutics
Spero Therapeutics has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, HHS and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on solutions targeting resistant micro-organisms
|
Founded Year | Domain | Location | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Spero Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Spero Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Spero Therapeutics Comparisons
Competitors of Spero Therapeutics
Spero Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nabriva, Melinta Therapeutics, Iterum Therapeutics, Adaptive Phage Therapeutics and Paratek Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| domain | founded_year | HQ Location |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| domain | founded_year | HQ Location |
Developer of antibiotics for MDR infections
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| domain | founded_year | HQ Location |
Therapeutics for antimicrobial resistant infections are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Spero Therapeutics
Frequently Asked Questions about Spero Therapeutics
When was Spero Therapeutics founded?
Spero Therapeutics was founded in 2013.
Where is Spero Therapeutics located?
Spero Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Spero Therapeutics a funded company?
Spero Therapeutics is a funded company, having raised a total of $114.7M across 13 funding rounds to date. The company's 1st funding round was a Post-IPO of $40M, raised on Apr 01, 2013.
How many employees does Spero Therapeutics have?
As of Dec 31, 2024, the latest employee count at Spero Therapeutics is 32.
What is the annual revenue of Spero Therapeutics?
Annual revenue of Spero Therapeutics is $27.4M as on Dec 31, 2024.
What does Spero Therapeutics do?
Developer of therapeutics for drug-resistant bacterial infections. It offers a portfolio of novel product candidates which includes Tebipenem HBr, an oral carbapenem for pediatric infections, SPR720, an oral antimicrobial agent for the treatment of non-tuberculous mycobacterial lung disease, and SPR206, an intravenous (IV)-administered next-generation polymyxin analog for gram-negative bacterial infections.
Who are the top competitors of Spero Therapeutics?
Spero Therapeutics's top competitors include Melinta Therapeutics, Vedanta Biosciences and Cubist Pharmaceuticals.
What products or services does Spero Therapeutics offer?
Spero Therapeutics offers Tebipenem HBr and SPR720.
Is Spero Therapeutics publicly traded?
Yes, Spero Therapeutics is publicly traded on NASDAQ under the ticker symbol SPRO.
Who are Spero Therapeutics's investors?
Spero Therapeutics has 15 investors. Key investors include Pfizer, HHS, RA Capital, CARB-X, and Atlas Venture.
What is Spero Therapeutics's ticker symbol?
The ticker symbol of Spero Therapeutics is SPRO on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.